Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENIALITY trial of teprenone for prevention of postoperative atrial fibrillation
NL-OMON59798Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of teprenone in Atrial fibrillation (AFib), sponsored by Amsterdam University Medical Center. Primary endpoint: Incidence of postoperative atrial fibrillation. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
teprenone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON59798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59798.